O
TRAW icon

OrbiMed’s Traws Pharma TRAW Stock Holding History

OrbiMed’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.11M Hold
605,531
– – 0.02% 112
2025
Q4 		$684K Hold
605,531
– – 0.01% 106
2025
Q3 		$1.12M Hold
605,531
– – 0.03% 102
2025
Q2 		$896K Hold
605,531
– – 0.02% 93
2025
Q1 		$1.39M Hold
605,531
– – 0.03% 97
2024
Q4 		$5.38M Hold
605,531
– – 0.11% 84
2024
Q3 		$3.56M Buy
605,531
+563,721
+1,348% +$5.13M 0.06% 103
2024
Q2 		$467K Buy
+41,810
New +$674K 0.01% 112

Other funds holding TRAW

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $478M AUM 50.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

OrbiMed's TRAW Position: Q1 2026 in Review

OrbiMed held its Traws Pharma (TRAW) position steady in Q1 2026 at 605,531 shares worth $1.11M. The position accounts for 0.02% of the portfolio, ranked #112.

OrbiMed first reported a position in TRAW in Q2 2024 and has held it in 8 quarters since. The position peaked at $5.38M in Q4 2024. 28 funds tracked by Wall St. Rank hold TRAW as of Q1 2026.

  • OrbiMed held 605,531 shares of Traws Pharma worth $1.11M as of Q1 2026.
  • OrbiMed left its Traws Pharma share count unchanged in Q1 2026.
  • Traws Pharma made up 0.02% of OrbiMed's portfolio in Q1 2026, its #112 holding.
  • OrbiMed first reported a position in Traws Pharma in Q2 2024 and has held it in 8 quarters since.
  • OrbiMed's Traws Pharma position peaked at $5.38M in Q4 2024.
  • 28 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.